ASCO 2025: Exercise programme may lower risk of recurrence and death for some colon cancer survivors
New study results show that a structured exercise programme following surgery and adjuvant chemotherapy reduced…
Browsing: ASCO
ASCO 2025: Perioperative treatment with durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers
Results from an international phase 3 clinical trial found that treating stage II, III, and…
ASCO 2025: Zanidatamab plus chemotherapy shows strong first-line efficacy in HER2-positive gastro-oesophageal adenocarcinoma
A phase 2 trial reports high response rates and durable outcomes in treatment-naive patients, presented…
ASCO 2025: ARCHES and Australian-led ENZAMET prostate cancer trials to present XTANDI® (enzalutamide) data
New data, to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting…
ASCO GU 2025: Some kidney cancer patients can stop combination treatment after two years
A new study presented today by researchers at Fox Chase Cancer Center shows that some…
ASCO GU 2025: New findings on tumour reduction and survival outcomes in advanced renal cell carcinoma
Thomas E. Hutsonchief of the Haematology Oncology Division at Texas Tech University Health Sciences Centre,…
ASCO GU 2025: Mobile prostate cancer screening clinic can help address barriers to serving high-risk communities
A new study from the UK found that a mobile prostate cancer screening clinic called…
ASCO GU 2025: Talazoparib and enzalutamide combination improves survival in some patients with prostate cancer
Patients with castration-resistant metastatic prostate cancer with or without HRR gene alterations treated with a…
ASCO GU 2025: ENZA-p combination treatment improves survival for metastatic prostate cancer
New research findings were reported today from the ENZA-p study (ANZUP 1901), led by the…
The OJC Episode 7: ASCO Special Episode Part 2
Welcome to Episode 6 of the second series of The Oncology Journal Club! Our Host Craig Underhill is joined by Dr Kate Clarke and Professor Christopher Jackson for the first ASCO 2024 Special.